EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Kidney cancer screening: novel concepts beyond population-level screening

Sabrina Helena Rossi, Hannah Harrison, Oliver Byass, Jessica Kitt, Michelle Clark, Kerrie Massey, Jason Pawluk, David Blunt, Stewart Manning, Grant D Stewart

Kidney International · 2026-07 · 110 (1) · 70-77

DOI: 10.1016/j.kint.2026.02.039 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Kidney International, 2026-07. Verfasst von Sabrina Helena Rossi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK; Cancer Research UK (CRUK) Cambridge Centre, Cambridge Bio…. Hauptthemen laut MEDLINE: Kidney Neoplasms, Early Detection of Cancer, Mass Screening. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, The Mark Foundation for Cancer Research, University of Cambridge.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Screening for kidney cancer has been identified as a research priority by several independent initiatives. Previous work revealed that the relatively low prevalence of kidney cancer in untargeted asymptomatic individuals hinders the cost-effectiveness and clinical utility of population screening. We, therefore, undertake a comprehensive literature review summarizing novel screening concepts beyond whole population screening, including targeting high-risk populations (to increase disease prevalence), screening for kidney cancer in combination with other abdominal conditions (to reduce costs), or combining both of these approaches. Risk-stratified screening may be undertaken using phenotypic and/or genetic risk scores. Phenotypic risk scores for kidney cancer generally achieve reasonable discrimination (area under the receiver operating characteristic curve between 0.67 and 0.71 in a mixed sex cohort), with the best performing model being based on age, sex, body mass index, smoking status, hypertension diagnosis, and systolic and diastolic blood pressure. Adding genetic to phenotypic data is costly and provides only a negligible gain in discrimination (an increase in the area under the receiver operating characteristic curve of 0.007 from 0.716 to 0.723), meaning it is unlikely to represent a clinically useful strategy. Alternatively, screening for kidney cancer may be combined with other conditions to maximize efficiency, including multicancer early detection tests and combined screening using ultrasonography (concurrently with abdominal aortic aneurysm screening) or abdominal computed tomography (concurrently with lung cancer screening). The latter strategy is most promising and has the highest public acceptability. In summary, we highlight benefits and harms of different screening strategies beyond traditional population screening and offer a comprehensive and contemporary summary of recent advances in this field and future research avenues.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney NeoplasmsEarly Detection of CancerMass ScreeningHumansRisk FactorsPhenotypeRisk AssessmentPredictive Value of TestsGenetic Predisposition to DiseasePrevalence

Stichwörter der Autor:innen

early detectionkidney cancerscreening

Autor:innen und Institutionen

  • Department of Surgery, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK; Cancer Research UK (CRUK) Cambridge Centre, Cambridge Biomedical Campus, Cambridge, UK.
  • Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Department of Radiology, Hull University Teaching Hospital NHS Trust, Castle Hill Hospital, Cottingham, UK.
  • Department of Surgery, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.
  • Humber Health Partnership, Hull University Teaching Hospital NHS Trust, Castle Hill Hospital, Cottingham, UK.
  • NHS Lung Cancer Screening Programme, West Yorkshire and Harrogate Cancer Alliance Team, Wakefield, UK.

Förderung

  • Cancer Research UK
  • The Mark Foundation for Cancer Research
  • University of Cambridge
  • NIHR Cambridge Biomedical Research Centre

Zitieren

APA

Rossi, S. H., Harrison, H., Byass, O., Kitt, J., Clark, M., Massey, K., Pawluk, J., Blunt, D., Manning, S., & Stewart, G. D. (2026). Kidney cancer screening: novel concepts beyond population-level screening. Kidney International, 110(1), 70-77. https://doi.org/10.1016/j.kint.2026.02.039

Vancouver

Rossi SH, Harrison H, Byass O, Kitt J, Clark M, Massey K, et al. Kidney cancer screening: novel concepts beyond population-level screening. Kidney International. 2026;110(1):70-77. doi:10.1016/j.kint.2026.02.039

BibTeX
@article{Rossi2026,
  author = {Rossi, Sabrina Helena and Harrison, Hannah and Byass, Oliver and Kitt, Jessica and Clark, Michelle and Massey, Kerrie and Pawluk, Jason and Blunt, David and Manning, Stewart and Stewart, Grant D},
  title = {Kidney cancer screening: novel concepts beyond population-level screening},
  journal = {Kidney International},
  year = {2026},
  volume = {110},
  number = {1},
  pages = {70--77},
  doi = {10.1016/j.kint.2026.02.039}
}
Kostenlos starten →